Abstract
A rapid wound healing is beneficial for not only recovering esthetics but also reducing pain, complications and healthcare burdens. For such a purpose, continuous efforts have been taken to develop viable dressing material. Acellular dermal matrix (ADM) paste has been used to repair burn wounds and is shown to promote angiogenesis as well as fibroblast attachment and migration. However, its efficacy still needs to be significantly improved to meet clinical demands for accelerating acute skin wound healing. To approach this problem, we studied the added value of a human salivary peptide — Histatin 1 (Hst1). Hst1 was chosen because of its potency to promote the adhesion, spreading, migration, metabolic activity and cell-cell junction of major skin cells and endothelial cells. In this study, we hypothesized that ADM paste and Hst1 showed a better effect on the healing of surgically created acute skin wounds in mice since ADM paste may act as a slow release system for Hst1. Our results showed that the healing efficacy of 10 μM topically administrated Hst1 was significantly higher compared to the control (no Hst1, no ADM) from day 3 to day 10 post-surgery. In contrast, ADM alone failed in our system at all time points. Also, the combination of ADM paste and Hst1 did not show a better effect on percentage of wound healing. Histological analysis showed that 10 μM Hst1 was associated with maximal thickness of newly formed epidermal layer on day 7 as well as the largest collagen area on day 14. In addition, immunohistochemical staining showed that the number of CD31-positive blood vessels in the group of 10 μM Hst1 was 2.3 times compared to the control. The vascular endothelial growth factor (VEGF) expression in the groups of 10 μM Hst1 group and ADM + 10 μM Hst1 group was significantly higher compared with the control group. Furthermore, 10 μM Hst1 group was associated with significantly lower levels of CD68-positive macrophage number, interleukin-1β (IL-1β) expression and C-reactive protein (CRP) expression than those of the other groups (control, ADM alone and ADM + 10 μM Hst1). In contrast, ADM was only associated with significantly lower CD68-positive macrophage number and IL-1β expression in comparison with the control. The co-administration of Hst1 and ADM paste did not yield more beneficial effects than Hst1 alone. In conclusion, the topically administrated of 10 μM Hst1 could be a promising alternative dressing in managing acute wound healing.
Original language | English |
---|---|
Article number | 999 |
Number of pages | 12 |
Journal | Frontiers in Bioengineering and Biotechnology |
Volume | 8 |
DOIs | |
Publication status | Published - 19 Aug 2020 |
Funding
The authors would like to thank Mr. Yingen Pan (Department of Burn and Plastic Surgery, Qidong People’s Hospital, Jiangsu, China) for providing the ADM. The authors also would like to thank Ms. Haiyan Wang and Mr. Zhichao Zheng (Guangzhou Medical University, Guangzhou, China) for their assistance with the immunochemical staining. Funding. This research was funded by the National Natural Science Foundation of China, grant numbers 81671924 and 81272105; National Key Research and Development Plan of China, grant number 2017YFC1103301; Health and Medical Treatment Collaborative Innovation Major Special Projects of Guangzhou, grant number 201508020253; Science and Technology Key Project of Guangdong Province, grant number 2014B020212010; Science and Technology Planning Project of Guangdong Province of China, grant number 2015B020233012; Military Medical Innovation Special Projects, grant number 18CXZ029; Zhejiang Provincial Basic Public Welfare Research Project (grant number GJ19H140001); and China’s National Key R&D Programs (NKPs, grant number 2018YFB0407204). This research was funded by the National Natural Science Foundation of China, grant numbers 81671924 and 81272105; National Key Research and Development Plan of China, grant number 2017YFC1103301; Health and Medical Treatment Collaborative Innovation Major Special Projects of Guangzhou, grant number 201508020253; Science and Technology Key Project of Guangdong Province, grant number 2014B020212010; Science and Technology Planning Project of Guangdong Province of China, grant number 2015B020233012; Military Medical Innovation Special Projects, grant number 18CXZ029; Zhejiang Provincial Basic Public
Funders | Funder number |
---|---|
Health and Medical Treatment Collaborative Innovation Major Special Projects of Guangzhou | 201508020253 |
Zhejiang Provincial Basic Public | |
Zhejiang Provincial Basic Public Welfare Research Project | GJ19H140001 |
Guangzhou Medical University | |
National Natural Science Foundation of China | 81272105, 81671924 |
National Key Research and Development Program of China | 2017YFC1103301 |
Science and Technology Planning Project of Guangdong Province | 2015B020233012, 2014B020212010, 18CXZ029 |